{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Zeng X"],"funding":["NIA NIH HHS","National Institutes of Health","NIH HHS"],"pagination":["40"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11095038"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["19(1)"],"pubmed_abstract":["Alzheimer's disease (AD), the most common form of dementia, remains challenging to understand and treat despite decades of research and clinical investigation. This might be partly due to a lack of widely available and cost-effective modalities for diagnosis and prognosis. Recently, the blood-based AD biomarker field has seen significant progress driven by technological advances, mainly improved analytical sensitivity and precision of the assays and measurement platforms. Several blood-based biomarkers have shown high potential for accurately detecting AD pathophysiology. As a result, there has been considerable interest in applying these biomarkers for diagnosis and prognosis, as surrogate metrics to investigate the impact of various covariates on AD pathophysiology and to accelerate AD t"],"journal":["Molecular neurodegeneration"],"pubmed_title":["Alzheimer blood biomarkers: practical guidelines for study design, sample collection, processing, biobanking, measurement and result reporting."],"pmcid":["PMC11095038"],"funding_grant_id":["P30 AG066468","R01 AG083874"],"pubmed_authors":["Klunk WE","Cohen AD","Lee J","Zeng X","Tudorascu DL","Villemagne VL","Lopez OI","Zetterberg H","Berman SB","Ikonomovic MD","Kamboh MI","Sehrawat A","Pascoal TA","Snitz BE","Chen Y","Kofler J","Sweet RA","Pfister A","Lafferty TK","Karikari TK","Blennow K"],"additional_accession":[]},"is_claimable":false,"name":"Alzheimer blood biomarkers: practical guidelines for study design, sample collection, processing, biobanking, measurement and result reporting.","description":"Alzheimer's disease (AD), the most common form of dementia, remains challenging to understand and treat despite decades of research and clinical investigation. This might be partly due to a lack of widely available and cost-effective modalities for diagnosis and prognosis. Recently, the blood-based AD biomarker field has seen significant progress driven by technological advances, mainly improved analytical sensitivity and precision of the assays and measurement platforms. Several blood-based biomarkers have shown high potential for accurately detecting AD pathophysiology. As a result, there has been considerable interest in applying these biomarkers for diagnosis and prognosis, as surrogate metrics to investigate the impact of various covariates on AD pathophysiology and to accelerate AD t","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 May","modification":"2026-07-16T07:33:54.813Z","creation":"2026-07-09T10:44:04.255Z"},"accession":"S-EPMC11095038","cross_references":{"pubmed":["38750570"],"doi":["10.1186/s13024-024-00711-1"]}}